Md. Shah Amran

By Md. Shah Amran

The discovery of a new drug usually takes 10-15 years. Within this time period, the candidate drug is thoroughly screened for its beneficial as well as side effects. But the side, adverse or toxic effects cannot be detected to a full scale due to some special reasons. The beneficial effects and toxicity of new drugs and vaccines are usually studied by “Clinical trials”, which are divided into four categories ranging from clinical trial phases I to IV. During clinical trial phase-III, about 4,000-10,000 patients are involved and after passing this phase, the drug is allowed to enter into the global market. Then, billions of people, including those who were excluded in phase-III, may be administered with this drug. It is worthy to mention that these 4,000-10,000 patients may not show many of the side effects or toxic actions. The undetected adverse drug reactions (ADRs) are studied in clinical trial phase-IV, which is also known as post market surveillance. For this reason, the ADRs are compared with the tip of the iceberg, as it indicates the minor part of a major event. This phenomenon gave birth to a new branch of the pharmacology known as Pharmacovigilance.

Part of the book: New Insights into the Future of Pharmacoepidemiology and Drug Safety

By Md. Shah Amran, Nasiba Binte Bahar and Shopnil Akash

The cardiovascular system (CVS) is made up of the heart, blood vessels, and blood. The fundamental function of CVS is to transport substances to and from all parts of the body. The heart is the major pumping organ, pressurizing blood for circulation through the blood vessels; blood is propelled away from the heart in the arteries and returns to the heart through the veins. Cardiovascular disease (CVD) is an umbrella term for a number of inter-linked diseases, generally defined as coronary artery disease, cerebrovascular disease, high blood pressure, peripheral arterial disease, rheumatic and congenital heart diseases, arrhythmia, etc. Globally, CVDs are the leading cause of deaths, and according to the estimation of the World Health Organization (WHO), about 17.9 million people died from CVDs in 2019, accounting for 32% of all global deaths. About 75% of CVD deaths occur in low- and middle-income countries. This burden of CVDs can be decreased by careful risk reduction (such as lifestyle modification, smoking and alcohol cessation, weight optimization, physical exercise), and proper medical treatments, including herbal components. The prevention of CVDs can reduce the occurrence of major cardiovascular events, thereby reducing premature disability, morbidity, and mortality, while prolonging survival and quality of life.

Part of the book: Novel Pathogenesis and Treatments for Cardiovascular Disease